Innovations in cancers of the central nervous system
- Submission status
- Closed
- Submission deadline
This Collection aims to highlights the latest advances in research in brain cancers, with a focus on adult diffuse gliomas, glioblastomas, meningiomas and metastatic brain tumors. Tumors affecting the brain cause substantial morbidity and mortality and there is a significant need for improved detection, non-invasive monitoring strategies and more effective and durable treatments. The focus of the collection will be on recent advances in basic, translational and clinical research as well as offer expert commentary on strategies to move brain cancer diagnostics and therapeutics forward.
Topics of interest include:
- Advances in liquid biopsy for diagnosis and monitoring of nervous system cancers
- Preclinical disease models (patient-derived xenografts, organoids, genetically engineered models)
- Innovations in Immunotherapy
- Metabolic dysregulation in glioma
- Targeted therapies and resistance in brain tumors
- Cancer neuroscience and tumor-microenvironment
- Advances in imaging techniques
- Strategies for increasing CNS permeability of therapeutic agents
- Applications of Artificial Intelligence/Machine Learning to brain cancers
This Collection supports and amplifies research related to SDG 3.
Editors
-
Julie J. Miller
Massachusetts General Hospital, Harvard Medical School, USA.
-
Albert Kim
Massachusetts General Hospital, Harvard Medical School, USA.
Dr. Julie Miller is an Assistant Professor at Harvard Medical School and a Neuro-Oncologist within the Pappas Center for Neuro-Oncology in the Department of Neurology at Massachusetts General Hospital. Her research focuses on IDH-mutant gliomas, a class of brain tumors that are driven by mutations that regulate metabolism. She utilizes a combination of genetic, pharmacologic and metabolomic approaches in patient-derived glioma models to elucidate the metabolic and cellular pathways that are disrupted by mutant IDH, with the goal of developing novel treatment strategies.
Dr. Albert Kim is a Medical Oncologist with interests in using machine learning and Omics to develop precision-based treatment paradigms for cancer patients. He has a special interest in central nervous system metastases, and his laboratory efforts leverage Omics-based techniques, medical imaging, and machine learning to define and target genomic and metabolic vulnerabilities for these tumors. Dr Kim hopes that these efforts will result in newer and smarter ways to treat these difficult diseases.
